Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Integra Lifesciences (IART)

Integra LifeSciences posts $484.1 million Q2 net loss on $511 million goodwill charge

Negative Impact 4 of 5 earnings Written later

Integra LifeSciences reported second-quarter 2025 revenue of $415.6 million, down 0.6% from a year earlier, and adjusted earnings of $0.45 per diluted share, versus $0.63 a year earlier. A $511 million goodwill impairment charge drove a GAAP net loss of $484.1 million, or $(6.31) per diluted share. The company updated its full-year revenue guidance to $1.655 billion to $1.680 billion and reaffirmed adjusted EPS guidance of $2.19 to $2.29.

Key points

  • Revenue $415.6 million, down 0.6% reported and 1.4% organic versus Q2 2024
  • GAAP net loss $484.1 million, or $(6.31) per diluted share, versus $(12.4) million a year earlier, mainly from the $511 million goodwill impairment
  • Adjusted EPS $0.45 versus $0.63; Q3 2025 adjusted EPS expected at $0.40 to $0.45
  • Net debt $1.59 billion at June 30, 2025; total leverage ratio 4.5x

The filing

CompanyIntegra Lifesciences (IART)
Form8-K, current report
Filed with the SECJul 31, 2025, 6:15 AM ET
Accession number0000917520-25-000069

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 6:59 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 31, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.